CA2540108A1 - Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor - Google Patents
Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor Download PDFInfo
- Publication number
- CA2540108A1 CA2540108A1 CA002540108A CA2540108A CA2540108A1 CA 2540108 A1 CA2540108 A1 CA 2540108A1 CA 002540108 A CA002540108 A CA 002540108A CA 2540108 A CA2540108 A CA 2540108A CA 2540108 A1 CA2540108 A1 CA 2540108A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- topoisomerase
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 title claims abstract description 95
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 title claims abstract description 95
- 239000003276 histone deacetylase inhibitor Substances 0.000 title claims description 73
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title claims description 71
- 230000000259 anti-tumor effect Effects 0.000 title claims description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 193
- 229960002550 amrubicin Drugs 0.000 claims abstract description 59
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims abstract description 59
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 201000011510 cancer Diseases 0.000 claims abstract description 25
- 239000002246 antineoplastic agent Substances 0.000 claims description 99
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 64
- 229940041181 antineoplastic drug Drugs 0.000 claims description 64
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 46
- 239000003623 enhancer Substances 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 23
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 20
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 20
- 229960001220 amsacrine Drugs 0.000 claims description 20
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 20
- 229960000975 daunorubicin Drugs 0.000 claims description 20
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 20
- 229960005420 etoposide Drugs 0.000 claims description 20
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 20
- 229960001156 mitoxantrone Drugs 0.000 claims description 20
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 20
- 229960001278 teniposide Drugs 0.000 claims description 20
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 19
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 19
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 19
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 19
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims description 19
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 claims description 19
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 19
- 229960004176 aclarubicin Drugs 0.000 claims description 19
- 229960004679 doxorubicin Drugs 0.000 claims description 19
- 229960001904 epirubicin Drugs 0.000 claims description 19
- 229960000908 idarubicin Drugs 0.000 claims description 19
- 229960001221 pirarubicin Drugs 0.000 claims description 19
- 229950010372 sobuzoxane Drugs 0.000 claims description 19
- 208000032839 leukemia Diseases 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 13
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 13
- 206010025323 Lymphomas Diseases 0.000 claims description 13
- 206010038389 Renal cancer Diseases 0.000 claims description 13
- 201000010982 kidney cancer Diseases 0.000 claims description 13
- 201000005202 lung cancer Diseases 0.000 claims description 13
- 208000020816 lung neoplasm Diseases 0.000 claims description 13
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims description 13
- 206010005003 Bladder cancer Diseases 0.000 claims description 12
- 206010033128 Ovarian cancer Diseases 0.000 claims description 12
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 12
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 12
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 12
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 12
- 229940000425 combination drug Drugs 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 229940126062 Compound A Drugs 0.000 description 28
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 9
- 102000003964 Histone deacetylase Human genes 0.000 description 8
- 108090000353 Histone deacetylase Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108010033040 Histones Proteins 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 6
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- -1 alkali metal salts Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 108010047956 Nucleosomes Proteins 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001623 nucleosome Anatomy 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 241000588881 Chromobacterium Species 0.000 description 3
- 102100039869 Histone H2B type F-S Human genes 0.000 description 3
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 2
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000011765 DBA/2 mouse Methods 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical class CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- ICBZSKCTKKUQSY-YUWZRIFDSA-N 4-[(1r,2s)-1-hydroxy-2-(methylamino)propyl]phenol;hydrochloride Chemical class Cl.CN[C@@H](C)[C@H](O)C1=CC=C(O)C=C1 ICBZSKCTKKUQSY-YUWZRIFDSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000941525 Chromobacterium sp. Species 0.000 description 1
- 241000588879 Chromobacterium violaceum Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 229930189037 Trapoxin Natural products 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- WPSXZFTVLIAPCN-WDSKDSINSA-N Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(O)=O WPSXZFTVLIAPCN-WDSKDSINSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 108010082820 apicidin Proteins 0.000 description 1
- 229930186608 apicidin Natural products 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229940035857 doxorubicin hydrochloride 10 mg Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 230000006197 histone deacetylation Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 108010060597 trapoxin A Proteins 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
A compound of formula I:
or a pharmaceutically acceptable salt thereof, in combination with a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof, for use in treatment of cancer.
Description
DESCRIPTION
ANTITUMOR AGENT
Technical Field The present invention relates to a pharmaceutical composition comprising, in combination, a topoisomerase II
inhibitor and a pharmaceutical agent that remarkably enhances an antitumor effect of the inhibitor, such as a histone deacetylase inhibitor, and methods of using such topoisomerase II inhibitors and histone deacetylase inhibitors.
z° Background Art Generally, in chemotherapy of tumor, particularly malignant tumor, an exclusive administration of an antitumor agent rarely results in a desired antitumor effect. To enhance the effect, a multiple drug therapy using, in combination, 2, 3 Z5 or more drugs having different action mechanisms, has been employed in clinical situations. In this combination therapy, antitumor agents having different action mechanisms are combined 1) to decrease insensitive cell population, 2) to prevent or delay appearance of drug-resistance, 3) to disperse 2o toxicity by the combination of pharmaceutical agents having different toxicities, and the like, thereby decreasing side effects and enhancing antitumor action. However, aimless combination of antitumor agents having different action mechanisms for combination therapy does not necessarily lead to an enhanced antitumor effect, and therefore, a combination effect afforded by the combination of antitumor agents exhibiting higher antitumor activities has been studied.
It has been reported that a compound represented by the formula (I) O CHs / CH ~- C-~.. N \ ~/CH
O~ ~ ~ ~ / O
C S C
CH - CH S NH
CH3 ' CHI
H2C CH ~ CH
C ~H C ~ ~ CH3 HC ' ~ CHs O H.~,-.. C,--- O O
z H
and a pharmaceutically acceptable salt thereof (hereinafter to be also referred to as compound A; SEQ ID; No 1), and particularly a stereoisomer of the formula (II) O
HN
NH
O S
HN (II) (hereinafter to be also referred to as FK228) and a pharmaceutically acceptable salt thereof strongly and selectively inhibit histone deacetylase to derive a potent antitumor activity, and that the substances cause high acetylation of histone in the treated cells, thereby inducing transcription-regulatory activity of various genes, cell cycle zo inhibitory activity and apoptosis (e. g., JP-B-7-64873, "Experimental Cell Research", US (1998), vol. 241, pp. 126-133).
However, there is no report as yet on the combined use of a histone deacetylase inhibitor such as Compound A and the like, and a topoisomerase II inhibitor, and the effect afforded by the combined use.
Histone deacetylase is a metallo-deacetylating enzyme coordinating Zn at an active center (M. S. Finnin et al., Nature, 401, 188-193 (1999)). This enzyme is considered to change affinity of various acetylated histones for DNA. The direct biological phenomenon brought thereby is a change in the chromatin structure. The minimum unit of the chromatin so structure is a nucleosome wherein 146 by DNA is wound 1.8 times anticlockwise around a histone octamer (H2A, H2B, H3 and H4, each 2 molecules, core histone). The core histone stabilizes the nucleosome structure by interaction of the positive charge of the N-terminus of each histone protein with DNA.
z5 Acetylation of histone is controlled by the equilibrium between an acetylation reaction involving histone acetyltransferase and a deacetylation reaction involving histone deacetylase. It is considered that the histone acetylation occurs at a lysine residue where the histone protein N-terminal is evolutionally 2o preserved well, due to which a core histone protein loses charges at the N-terminal, interaction with DNA is attenuated, and the structure of nucleosome becomes unstable. Accordingly, the histone deacetylation is considered to be the reverse thereof, namely, a shift toward stabilization of the nucleosome 25 structure. However, to what degree the acetylation changes the chromatin structure and how it relates to the transcriptional regulation etc. secondarily induced thereby are unclear in many aspects.
An object of the present invention is to provide an 3o antitumor agent causing reduced side-effects and a superior antitumor activity based on the combined use of a topoisomerase II inhibitor as an antitumor agent, and a pharmaceutical agent that strikingly enhances an antitumor effect of the inhibitor.
Disclosure of the Invention The present inventors have conducted extensive studies, and as a result, have found that histone deacetylase inhibitors, particularly Compound A and FK228, remarkably enhance the antitumor effect of topoisomerase II inhibitors, and completed the present invention. Accordingly, the present invention includes the following:
[1] An antitumor agent comprising a combination of a histone deacetylase inhibitor and a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
[2] The antitumor agent of [1] above, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobu~oxane, amsacrine, teniposide, and z5 pharmaceutically acceptable salts thereof.
[3] The antitumor agent of [2] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II
inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
ANTITUMOR AGENT
Technical Field The present invention relates to a pharmaceutical composition comprising, in combination, a topoisomerase II
inhibitor and a pharmaceutical agent that remarkably enhances an antitumor effect of the inhibitor, such as a histone deacetylase inhibitor, and methods of using such topoisomerase II inhibitors and histone deacetylase inhibitors.
z° Background Art Generally, in chemotherapy of tumor, particularly malignant tumor, an exclusive administration of an antitumor agent rarely results in a desired antitumor effect. To enhance the effect, a multiple drug therapy using, in combination, 2, 3 Z5 or more drugs having different action mechanisms, has been employed in clinical situations. In this combination therapy, antitumor agents having different action mechanisms are combined 1) to decrease insensitive cell population, 2) to prevent or delay appearance of drug-resistance, 3) to disperse 2o toxicity by the combination of pharmaceutical agents having different toxicities, and the like, thereby decreasing side effects and enhancing antitumor action. However, aimless combination of antitumor agents having different action mechanisms for combination therapy does not necessarily lead to an enhanced antitumor effect, and therefore, a combination effect afforded by the combination of antitumor agents exhibiting higher antitumor activities has been studied.
It has been reported that a compound represented by the formula (I) O CHs / CH ~- C-~.. N \ ~/CH
O~ ~ ~ ~ / O
C S C
CH - CH S NH
CH3 ' CHI
H2C CH ~ CH
C ~H C ~ ~ CH3 HC ' ~ CHs O H.~,-.. C,--- O O
z H
and a pharmaceutically acceptable salt thereof (hereinafter to be also referred to as compound A; SEQ ID; No 1), and particularly a stereoisomer of the formula (II) O
HN
NH
O S
HN (II) (hereinafter to be also referred to as FK228) and a pharmaceutically acceptable salt thereof strongly and selectively inhibit histone deacetylase to derive a potent antitumor activity, and that the substances cause high acetylation of histone in the treated cells, thereby inducing transcription-regulatory activity of various genes, cell cycle zo inhibitory activity and apoptosis (e. g., JP-B-7-64873, "Experimental Cell Research", US (1998), vol. 241, pp. 126-133).
However, there is no report as yet on the combined use of a histone deacetylase inhibitor such as Compound A and the like, and a topoisomerase II inhibitor, and the effect afforded by the combined use.
Histone deacetylase is a metallo-deacetylating enzyme coordinating Zn at an active center (M. S. Finnin et al., Nature, 401, 188-193 (1999)). This enzyme is considered to change affinity of various acetylated histones for DNA. The direct biological phenomenon brought thereby is a change in the chromatin structure. The minimum unit of the chromatin so structure is a nucleosome wherein 146 by DNA is wound 1.8 times anticlockwise around a histone octamer (H2A, H2B, H3 and H4, each 2 molecules, core histone). The core histone stabilizes the nucleosome structure by interaction of the positive charge of the N-terminus of each histone protein with DNA.
z5 Acetylation of histone is controlled by the equilibrium between an acetylation reaction involving histone acetyltransferase and a deacetylation reaction involving histone deacetylase. It is considered that the histone acetylation occurs at a lysine residue where the histone protein N-terminal is evolutionally 2o preserved well, due to which a core histone protein loses charges at the N-terminal, interaction with DNA is attenuated, and the structure of nucleosome becomes unstable. Accordingly, the histone deacetylation is considered to be the reverse thereof, namely, a shift toward stabilization of the nucleosome 25 structure. However, to what degree the acetylation changes the chromatin structure and how it relates to the transcriptional regulation etc. secondarily induced thereby are unclear in many aspects.
An object of the present invention is to provide an 3o antitumor agent causing reduced side-effects and a superior antitumor activity based on the combined use of a topoisomerase II inhibitor as an antitumor agent, and a pharmaceutical agent that strikingly enhances an antitumor effect of the inhibitor.
Disclosure of the Invention The present inventors have conducted extensive studies, and as a result, have found that histone deacetylase inhibitors, particularly Compound A and FK228, remarkably enhance the antitumor effect of topoisomerase II inhibitors, and completed the present invention. Accordingly, the present invention includes the following:
[1] An antitumor agent comprising a combination of a histone deacetylase inhibitor and a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
[2] The antitumor agent of [1] above, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobu~oxane, amsacrine, teniposide, and z5 pharmaceutically acceptable salts thereof.
[3] The antitumor agent of [2] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II
inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[4] The antitumor agent of [3] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically 25 acceptable salts thereof.
[5] The antitumor agent of any of [1] to [4] above, which is used for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
[6] An antitumor effect enhancer of a topoisomerase II
inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof, which comprises a histone deacetylase inhibitor as an active ingredient.
inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof, which comprises a histone deacetylase inhibitor as an active ingredient.
[7] The enhancer of [6] above, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
[8] The enhancer of [7] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a so pharmaceutically acceptable salt thereof.
[9] The enhancer of [8] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically z5 acceptable salts thereof.
[10] The enhancer of any of [6] to [9] above, which is used for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
20 [11] A method for treating a cancer, which comprises administrating, to a mammal, a combination of an effective amount of a histone deacetylase inhibitor and an effective amount of a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
[12] The method of [11] above, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and 3o pharmaceutically acceptable salts thereof.
[13] The method of [12] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[14] The method of [13] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[15] The method of any of [11] to [14] above, wherein the cancer is lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder so cancer, leukemia, kidney cancer or prostate cancer.
[16] A method of enhancing an antitumor effect of a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof, which comprises administrating an effective amount of a histone deacetylase i5 inhibitor to a mammal.
[17] The method of [16] above, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, 2o mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
[18] The method of [17] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically 25 acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[19] The method of [18] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, so daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[~0] The method of any of [16] to [19] above, which enhances an antitumor effect against lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
[21] Use of a histone deacetylase inhibitor and a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof, for producing an antitumor agent.
[22] The use of [21] above, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, so mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
[23] The use of [22] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically 15 acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[24] The use of [23] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, 2o daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[25] The use of any of [21] to [24] above, wherein the antitumor agent is used for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, 25 chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
[26] Use of a histone deacetylase inhibitor for producing an antitumor effect enhancer of a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
30 [27] The use of [26] above, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
[28] The use of [27] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[29] The use of [28] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, 1o daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[30] The use of any of [26] to [29] above, wherein the antitumor effect enhancer is used for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian Is cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
[31] A pharmaceutical composition comprising, as active ingredients, a histone deacetylase inhibitor and a topoisomerase II inhibitor, except amrubicin and a 2o pharmaceutically acceptable salt thereof.
[32] The pharmaceutical composition of [31] above, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, 25 etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
[33] The pharmaceutical composition of [32] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug 30 or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[34] The pharmaceutical composition of [33] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[35] A commercial package comprising a combination drug containing a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination, except amrubicin and a pharmaceutically acceptable salt thereof, and a written matter associated with the combination drug, the written matter stating that the combination drug can or should be used for an antitumor agent.
To [36] The commercial package of [35] above, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and 15 pharmaceutically acceptable salts thereof.
[37] The commercial package described in [36] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin 2o and a pharmaceutically acceptable salt thereof.
[38] The commercial package of [37] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[39] A commercial package comprising a preparation containing a histone deacetylase inhibitor, and a written matter associated with therewith, the written matter stating that the preparation can or should be used for enhancing the antitumor effect of a so topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
[40] The commercial package of [39] above, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
[41] The commercial package of [40] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II
inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[42] The commercial package of [41] above, wherein the so anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
Detailed Description of the Tnvention z5 The "histone deacetylase inhibitor" or (HDAC inhibitors) in the present invention is a compound that binds to an active site of histone deacetylase competitively with substrates, or a compound that binds to a different site from active site of histone deacetylase to change the enzyme activity of histone 2o deacetylase and/or decreases the enzymatic activity of histone deacetylase or otherwise inhibits enzyme activity. To be specific, the aforementioned Compound A, FK228, salts thereof and derivatives thereof (e. g., acetylated Compound A, thiol form with reduced S-S bond described in WO 02/06307, and 25 prodrugs thereof) can be mentioned. Analogs of FK228 are described in US Patent No. 6,403,555. In addition, Trichostatin A, sodium butyrate, suberoylanilide hydroxamic acid (SAHA), MS-275, cyclic hydroxamic-acid-containing peptide, Apicidin, Trapoxin and the like are the compounds reported to have a 3o histone deacetylase inhibitory activity. The inhibitors can be administered or used alone or in combination with one or more additional histone deacetylase inhibitors.
"Compound A" or "compound A", used interchangeably herein, includes its stereoisomers (e.g., FK 228) based on an asymmetric carbon atom or a double bond, such as an optically active form, a geometric isomer, racemic mixtures and the like.
Moreover, polymorphic forms, solvates (e. g., inclusion compounds (e.g., hydrate etc.)) and anhydrous forms of the compounds described herein, such as compound A, FK 228 and pharmaceutically acceptable salts thereof, are also encompassed in the scope of the present invention.
In the present specification, unless particularly specified, a simple reference to compound A includes any member 20 of the group of compounds regardless of stereoisomerism, and includes FK 228 or pharmaceutically acceptable salt thereof.
The compound A or a salt thereof are known and available substances. For example, FK 228, which is one of the stereoisomers of compound A, can be obtained by culturing a z5 strain belonging to the genus Chromobacterium, which is capable of producing FK 228, under aerobic conditions, and harvesting the substance from its culture broth. As the strain belonging to the genus Chromobacterium, which is capable of producing FK
228, for example, Chromobacterium violaceum WB968 (FERM BP-20 1968) can be mentioned. More specifically, FK 228 can be obtained from a FK 228 producing strain as described in JP-B-7-64872 (corresponding to US Patent No. 4977138, which is incorporated herein by reference). FK 228 is preferably harvested from a strain belonging to the genus Chromobacterium, 25 which is capable of producing FK 228, because it can be obtained more easily. Synthetic or semi-synthetic FK 228 is also advantageous in that further purification step is not necessary or the number of steps can be reduced. Similarly, compounds A other than FK 228 can be also obtained by semi-3o synthesis or total synthesis by conventionally known methods.
To be more specific, it can be produced according to the method reported by Khan W. Li, et al. (J. Am. Chem. Soc., Vol. 118, 7237-7238(1996)).
The form of a pharmaceutically acceptable salt of compound A, or other HDAC inhibitors, includes salts with a base or an acid addition salt such as salts with inorganic base (e. g., alkali metal salts such as sodium salt, potassium salt etc., alkaline earth metal salts such as calcium salt, magnesium salt etc., ammonium salt), salts with an organic base (e. g., organic amine salts such as triethylamine salt, diisopropylethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt etc.), inorganic acid 1o addition salts (e. g., hydrochloride, hydrobromide, sulfate, phosphate etc.), organic carboxylic acid or sulfonic acid addition salts (e. g., formate, acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate etc.), salts with a basic or acidic amino acid s5 (e.g., arginine, aspartic acid, glutamic acid etc.) and the like.
The "topoisomerase II inhibitor'° in the present invention is a compound that binds to an active site of topoisomerase II
competitively with substrates, or a compound that binds to a 2o different site from active site of topoisomerase II to change the enzyme activity of topoisomerase II, and/or a compound that decreases the enzyme activity of topoisomerase II or otherwise inhibits enzyme activity. To be specific, anthracycline anticancer drugs, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide and the like, and pharmaceutically acceptable salts thereof and combinations thereof can be mentioned.
The anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, which is used as a topoisomerase II
3o inhibitor in the present invention, is not particularly limited.
Generally, amrubicin or a pharmaceutically acceptable salt thereof is not included in the scope of the present invention, which embodiment is described and claimed in copending application No. 334344/2003 filed in Japan on the same date as the patent application No. 334340/2003 filed in Japan forming the basis of this application. This copending application is incorporated herein by reference in its entirety. For example, aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin (adriamycin), pirarubicin and the like, and pharmaceutically acceptable salts thereof can be mentioned, with preference given to doxorubicin, daunorubicin and pharmaceutically acceptable salts thereof. The anthracycline anticancer drug or a pharmaceutically acceptable salt thereof may be used alone or so in a mixture of two or more kinds thereof.
In the present specification, the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is intended to exclude amrubicin and a pharmaceutically acceptable salt thereof, unless otherwise indicated.
15 As pharmaceutically acceptable salts of anthracycline anticancer drug, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide and the like, salts with a base or an acid addition salt such as salts with inorganic base (e. g., alkali metal salts such as sodium salt, potassium salt etc., alkaline earth 2o metal salts such as calcium salt, magnesium salt etc., ammonium salt), salts with an organic base (e. g., organic amine salts such as triethylamine salt, diisopropylethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-25 diben~ylethylenediamine salt etc.), inorganic acid addition salts (e. g., hydrochloride, hydrobromide, sulfate, phosphate etc.), organic carboxylic acid or sulfonic acid addition salts (e. g., formats, acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate 3o etc.), salts with a basic or acidic amino acid (e. g., arginine, aspartic acid, glutamic acid etc.) and the like can be mentioned.
In the present invention, the histone deacetylase inhibitor such as Compound A and the like, markedly enhances the antitumor activity of topoisomerase II inhibitor such as an anthracycline anticancer drug, a pharmaceutically acceptable salt thereof and the like. Thus, the antitumor agent and the antitumor effect enhancer of the present invention are useful as therapeutic drugs for cancer diseases including blood cancer and solid cancer, which are more specifically lung cancer, malignant lymphoma (e. g., reticulosarcoma, lymphosarcoma, Hodgkin's disease and the like), cancer of digestive organ (e. g., gastric cancer, gallbladder~bile duct cancer, pancreatic Zo cancer., liver cancer, colon cancer, rectal cancer and the like), breast cancer, ovarian cancer, chondrosarcoma (e. g., osteosarcoma and the like), bladder cancer, leukemia (e. g., acute leukemia such as acute inversion of chronic myeloid leukemia and the like), kidney cancer, prostate cancer and the s5 like .
The antitumor agent of the present invention is a combination of a histone deacetylase inhibitor and a topoisomerase II inhibitor (i.e., combination drug), and may be any as long as a histone deacetylase inhibitor and a ~o topoisomerase II inhibitor can be combined when in use for the administration. Therefore, the antitumor agent of the present invention may be a single preparation obtained by simultaneously preparing a histone deacetylase inhibitor and a topoisomerase II inhibitor, or a combined preparation 25 comprising two or more preparations obtained by separately processing a histone deacetylase inhibitor and a topoisomerase II inhibitor, as long as a histone deacetylase inhibitor and a topoisomerase II inhibitor can be combined when in use for the administration.
3o The form of administration is not particularly limited, and, for example, (1) administration of a composition comprising a histone deacetylase inhibitor and a topoisomerase II inhibitor, i.e., a single preparation, (2) simultaneous administration of two kinds of preparations obtained by separately processing the histone deacetylase inhibitor and the topoisomerase II inhibitor by the same administration route, (3) time staggered administration of two kinds of preparations obtained by separately processing a histone deacetylase inhibitor and a topoisomerase II inhibitor by the same administration route (e.g., administration in the order of a histone deacetylase inhibitor and a topoisomerase II inhibitor, or administration in reverse order), (4),simultaneous administration of two kinds of preparations obtained by separately processing a.histone deacetylase inhibitor and a topoisomerase II inhibitor by different administration routes, and (5) time staggered administration of two kinds of preparations obtained by separately preparing a histone deacetylase inhibitor and a topoisomerase II inhibitor by 25 different administration routes (e.g., administration in the order of a histone deacetylase inhibitor and a topoisomerase II
inhibitor, or administration in reverse order) and the like can be mentioned.
In the case of the time staggered administration, 2o moreover, it is preferred that a histone deacetylase inhibitor and a topoisomerase II inhibitor be co-present in the body for a time period necessary for the histone deacetylase inhibitor to reinforce the antitumor effect of the topoisomerase II
inhibitor. As such, it is preferred that the second inhibitor 25 is administered before the first inhibitor is cleared from the patient.
The enhancer of the present invention comprises a histone deacetylase inhibitor, and may be any as long as a histone deacetylase inhibitor and a topoisomerase II inhibitor can be so combined when in use for the administration. Therefore, as long as a histone deacetylase inhibitor is contained, the enhancer of the present invention may contain a topoisomerase II inhibitor in a single preparation. When it does not contain a topoisomerase II inhibitor, a topoisomerase II inhibitor can be administered separately as a combination drug.
The form of administration is not particularly limited, and, for example, (1) administration of an enhancer of the present invention, comprising a histone deacetylase inhibitor and a topoisomerase II inhibitor in a single preparation, (2) simultaneous administration of the enhancer of the present invention and a topoisomerase II inhibitor by the same administration route, (3) time staggered administration of the enhancer of the present invention and a topoisomerase II
so inhibitor by the same administration route (e. g., administration in the order of a topoisomerase II inhibitor and the enhancer of the present invention, or administration in reverse order), (4) simultaneous administration of the enhancer of the present invention and a topoisomerase II inhibitor by Zs different administration routes, and (5) time staggered administration of the enhancer of the present invention and a topoisomerase II inhibitor by different administration routes (e.g., administration in the order of a topoisomerase II
inhibitor and the enhancer of the present invention, or 2o administration in reverse order) and the like can be mentioned.
In addition, in the case of time staggered administration, both ingredients need to be co-present in the body as in the case of the above-mentioned antitumor agent.
In the present invention, the ratio of combination of the histone deacetylase inhibitor and the topoisomerase II
inhibitor is generally in the range of 1 . 100 to 100 . 1, preferably in the range of 1 . 10 to 10 . 1, in a weight ratio, whether they are prepared into a single preparation or separate preparations.
3o To enhance the antitumor effect of the present invention, administration along with ATRA (all-trans-retinoic acid) and other antitumor agents is also possible (e. g., administration as a single preparation, or simultaneous or sequential administration as separate preparations). In addition, the invention includes administering additional active agents that can treat or prevent side effects of one or more of the antitumor agents being administered.
The antitumor agent of the present invention can be used in the form of a pharmaceutical preparation such as a solid, semisolid or liquid preparation (tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, liquid, emulsion, suspension, syrup, injection etc.) containing a histone deacetylase inhibitor and/or topoisomerase II inhibitor to as an active ingredient, which is suitable for transrectal, intranasal, pulmonary, vaginal, external (topical), oral or parenteral (including subcutaneous, implantation, intravenous and intramuscular) administration.
The antitumor effect enhancer of the present invention z5 Can be used in the form of a pharmaceutical preparation such as a solid, semisolid or liquid preparation (tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, liquid, emulsion, suspension, syrup, injection etc.) containing a histone deacetylase inhibitor as an active ingredient, which 2o is suitable for transrectal, intranasal, pulmonary, vaginal, external (topical), oral or parenteral (including subcutaneous, implantation, intravenous and intramuscular) administration.
The antitumor agent and antitumor effect enhancer of the present invention can be also produced by conventional methods 2s using various organic or inorganic carriers conventionally used for forming pharmaceutical preparations, such as excipients (e. g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate etc.), condensation agents (e. g., cellulose, methyl cellulose, 3o hydroxypropyl cellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, starch etc.), disintegrants (e. g., starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, hydroxypropyl starch, sodium starch glycolate, sodium hydrogen carbonate, calcium phosphate, calcium citrate etc.), lubricants (e. g., magnesium stearate, aerosil, talc, sodium lauryl sulfate etc.), corrigents (e. g., citric acid, menthol, glycine, orange powder etc.), preservatives (e. g., sodium benzoate, sodium hydrogen sulfite, methylparaben, propylparaben etc.), stabilizers (citric acid, sodium citrate, acetic acid etc.), suspensions (e. g., methyl cellulose, polyvinyl pyrrolidone, aluminum stearate etc.), dispersants (e. g., hydroxypropylmethyl cellulose etc.), diluents (e. g., water etc.), wax base materials (e. g., cacao 2o butter, polyethylene glycol, white petrolatum etc.) and the like.
The antitumor agent and the antitumor effect enhancer of the present invention can be administered, without any particular limitation, in the form of the above-mentioned s5 conventional pharmaceutical preparations, to mammals inclusive of human. Particularly, they are preferably administered intravenously, intramuscularly or orally.
The dose in the present invention can be set to a lower level, as compared to an exclusive administration of a histone deacetylase inhibitor or a topoisomerase II inhibitor.
For example, the dose is selected appropriately depending on various factors such as the body weight and/or age of patients, and/or the degree of the symptom and an administration route. For example, when Compound A was added 2s as a histone deacetylase inhibitor, and an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof was added as a topoisomerase II inhibitor, the dose of a combination of Compound A and an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof for intravenous 3o administration is generally in the range of 1 to 1000 mg/day/m~
human body surface area, preferably in the range of 5 to 100 mg/day/m~ human body surface area, and more preferably 10 to 60 mg/day/m~ human body surface area by continuous drip infusion administration. In this case, the dose of Compound A is 0.1 to 100 mg/day/m2 human body surface area, preferably 1 to 50 mg/day/m2 human body surface area, and more preferably 5 to 30 mg/day/m~ human body surface area, wherein the dose of the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof to be administered is an amount obtained by subtracting the dose of Compound A from the combined dose of the above-mentioned Compound A and the anthracycline anticancer drug or the pharmaceutically acceptable salt thereof.
The present invention also provides a commercial package so comprising a combination drug containing a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination, except amrubicin and a pharmaceutically acceptable salt thereof, and a written matter associated with the combination drug, the written matter stating that the combination drug can or should 25 be used for an antitumor agent; and a commercial package comprising a preparation containing a histone deacetylase inhibitor, and a written matter associated with the preparation, the written matter stating that the preparation can or should be used for enhancing the antitumor effect of a topoisomerase 2o II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
Examples To demonstrate the usefulness of the present invention, the results of a pharmacological test are shown in the following.
Experimental Method 1 For an animal, 6 to 12-week-old female CDF1 mice (body weight: 17.2 to 24.7 g) were used at 5 to 12 mice per group.
Furthermore, female DBA/2 mice were used for the subculture of 3o tumor cells. For tumor, L-1210 mouse leukemia cells (hereinafter to be referred to as L-1210) were used. L-1210 cells subcultured intraperitoneally in DBA/2 mice were harvested and washed twice with a Hanks' solution. Dead cells were stained with trypan blue, viable cells were counted, and then the cells were suspended in a Hanks' solution, whereby the cells were adjusted to a predetermined number of cells. For the experiment, L-1210 cells (1 ~ 105 cells) were implanted intraperitoneally into the CDF1 mice.
The test compound was administered intraperitoneally into the mice once a day for 4 days, starting from the day after implantation of the tumor cells (dose: diluted test compound is administered at 10 ml/kg). In combined use experiment of the test compound, FK228 and the test compound were administered To sequentially.
All the antitumor effects were evaluated using prolonged life of mice as an index.
For the survival period of the mice, the survival was observed over 30 days or 60 days after tumor implantation, a 1s Median Survival Time (hereinafter to be referred to as MST) was determined and the life prolonging rate was calculated from the following formula:
MST of test compound 2o administration group Life prolonging rate = X 100 [T/C (%)] MST of control group The combination effect was determined by calculating a 25 Combination Index (C. I.) from the following formula, wherein C.I. > 1 was evaluated to be synergistic effect; C.I. - 1 was evaluated to be addition effect; and C.I. < 1 was evaluated to be no combination effect.
3o T/C [o] of FK228 and the test compound combined use group - 100 C.I.=
CT/C [ o ] of FK228 alone + rT/C [ o ] of test compound group - 100 I' alone group - 100 Test Compound 1 Adriamycin was dissolved in distilled water, and diluted with physiological saline. Other test compounds were dissolved in physiological saline, and then diluted with physiological saline.
Test Results 1 The results are shown in Table 1.
Table 1 Combination effect by combined use 1 [6 mice per group (12 mice per group for control group)]
Test compound Dose (mg/mg) T/C (%) C.I.
0.14 + 0 100 -FK228 + adriamycin 0 + 1 133 -0.14 + 1 178 2.36 The combined use of FK228 and adriamycin revealed a C.I.
of 2.36, which was evaluated to suggest a synergistic effect.
In addition, 2 mice out of 6 mice survived for 30 days.
As is clear from the results, the combined use of 0.14 mg/kg of FK228 ineffective by exclusive use and 1 mg/kg of adriamycin synergistically enhanced the antitumor effect thereof. Thus, FK228 is extremely useful as an antitumor effect enhancer.
Formulation Example 1 FK228 20 mg 2° physiological saline 4 ml FK228 (20 mg) is dissolved in and diluted with 4 ml of physiological saline to obtain a preparation for injection.
Formulation Example 2 FK228 20 mg doxorubicin hydrochloride 10 mg physiological saline 4 ml FK228 (20 mg) and doxorubicin hydrochloride (10 mg) are dissolved in and diluted with 4 ml of physiological saline to obtain a preparation for injection.
Tndustrial Applicability A histone deacetylase inhibitor (particularly Compound A) remarkably enhances the antitumor effect of a topoisomerase II
inhibitor.
Therefore, the antitumor agent of the present invention comprising a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination provides higher cancer treatment effects with a lower dose as compared to an exclusive administration of a~histone deacetylase inhibitor or a topoisomerase II inhibitor, and moreover, can decrease the side 25 effects to a lower level.
This application is based on patent application Nos.
334340/2003 and 344315/2003 filed in Japan, the contents of which are hereby incorporated by reference.
2o While this invention has been shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompasses by the appended claims.
All patents, patent publications and other publications identified or referenced herein are incorporated by reference in their entirety.
SEQUENCE LISTING
<110> Fujisawa Pharmaceutical Co., Ltd.
<120> Antitumor agent <130> 09678 <150> JP 2003-33434 0 <151> 2003-09-25 <150> JP 2003-34431 5 <151> 2003-10-2 <160> 1 <210> 1 <211> 4 <212> PRT
<213> Chromobacterium sp.
<220>
<221> MISC FEATURE
<222> (3) <223> Xaa is an amino acid represented by the formula NHa C ( CHCH3 ) COOH .
<220>
<221> SITE
<222> (1) , (2) , (4) <223> In the formula COOHCHZ CH (CHCHCZ H4 SH) OH, the carboxylic group is bonded with the amino group of the first amino acid Val, the hydroxyl group is bonded with the carboxylic group of the fourth amino acid Val, and the SH group is bonded with the SH group of the second amino acid Cys via a disulfide bond.
<400> 1 Val Cys Xaa Val
20 [11] A method for treating a cancer, which comprises administrating, to a mammal, a combination of an effective amount of a histone deacetylase inhibitor and an effective amount of a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
[12] The method of [11] above, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and 3o pharmaceutically acceptable salts thereof.
[13] The method of [12] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[14] The method of [13] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[15] The method of any of [11] to [14] above, wherein the cancer is lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder so cancer, leukemia, kidney cancer or prostate cancer.
[16] A method of enhancing an antitumor effect of a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof, which comprises administrating an effective amount of a histone deacetylase i5 inhibitor to a mammal.
[17] The method of [16] above, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, 2o mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
[18] The method of [17] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically 25 acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[19] The method of [18] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, so daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[~0] The method of any of [16] to [19] above, which enhances an antitumor effect against lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
[21] Use of a histone deacetylase inhibitor and a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof, for producing an antitumor agent.
[22] The use of [21] above, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, so mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
[23] The use of [22] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically 15 acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[24] The use of [23] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, 2o daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[25] The use of any of [21] to [24] above, wherein the antitumor agent is used for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, 25 chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
[26] Use of a histone deacetylase inhibitor for producing an antitumor effect enhancer of a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
30 [27] The use of [26] above, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
[28] The use of [27] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[29] The use of [28] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, 1o daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[30] The use of any of [26] to [29] above, wherein the antitumor effect enhancer is used for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian Is cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
[31] A pharmaceutical composition comprising, as active ingredients, a histone deacetylase inhibitor and a topoisomerase II inhibitor, except amrubicin and a 2o pharmaceutically acceptable salt thereof.
[32] The pharmaceutical composition of [31] above, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, 25 etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
[33] The pharmaceutical composition of [32] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug 30 or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[34] The pharmaceutical composition of [33] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[35] A commercial package comprising a combination drug containing a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination, except amrubicin and a pharmaceutically acceptable salt thereof, and a written matter associated with the combination drug, the written matter stating that the combination drug can or should be used for an antitumor agent.
To [36] The commercial package of [35] above, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and 15 pharmaceutically acceptable salts thereof.
[37] The commercial package described in [36] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin 2o and a pharmaceutically acceptable salt thereof.
[38] The commercial package of [37] above, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
[39] A commercial package comprising a preparation containing a histone deacetylase inhibitor, and a written matter associated with therewith, the written matter stating that the preparation can or should be used for enhancing the antitumor effect of a so topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
[40] The commercial package of [39] above, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
[41] The commercial package of [40] above, wherein the histone deacetylase inhibitor is Compound A, and the topoisomerase II
inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
[42] The commercial package of [41] above, wherein the so anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
Detailed Description of the Tnvention z5 The "histone deacetylase inhibitor" or (HDAC inhibitors) in the present invention is a compound that binds to an active site of histone deacetylase competitively with substrates, or a compound that binds to a different site from active site of histone deacetylase to change the enzyme activity of histone 2o deacetylase and/or decreases the enzymatic activity of histone deacetylase or otherwise inhibits enzyme activity. To be specific, the aforementioned Compound A, FK228, salts thereof and derivatives thereof (e. g., acetylated Compound A, thiol form with reduced S-S bond described in WO 02/06307, and 25 prodrugs thereof) can be mentioned. Analogs of FK228 are described in US Patent No. 6,403,555. In addition, Trichostatin A, sodium butyrate, suberoylanilide hydroxamic acid (SAHA), MS-275, cyclic hydroxamic-acid-containing peptide, Apicidin, Trapoxin and the like are the compounds reported to have a 3o histone deacetylase inhibitory activity. The inhibitors can be administered or used alone or in combination with one or more additional histone deacetylase inhibitors.
"Compound A" or "compound A", used interchangeably herein, includes its stereoisomers (e.g., FK 228) based on an asymmetric carbon atom or a double bond, such as an optically active form, a geometric isomer, racemic mixtures and the like.
Moreover, polymorphic forms, solvates (e. g., inclusion compounds (e.g., hydrate etc.)) and anhydrous forms of the compounds described herein, such as compound A, FK 228 and pharmaceutically acceptable salts thereof, are also encompassed in the scope of the present invention.
In the present specification, unless particularly specified, a simple reference to compound A includes any member 20 of the group of compounds regardless of stereoisomerism, and includes FK 228 or pharmaceutically acceptable salt thereof.
The compound A or a salt thereof are known and available substances. For example, FK 228, which is one of the stereoisomers of compound A, can be obtained by culturing a z5 strain belonging to the genus Chromobacterium, which is capable of producing FK 228, under aerobic conditions, and harvesting the substance from its culture broth. As the strain belonging to the genus Chromobacterium, which is capable of producing FK
228, for example, Chromobacterium violaceum WB968 (FERM BP-20 1968) can be mentioned. More specifically, FK 228 can be obtained from a FK 228 producing strain as described in JP-B-7-64872 (corresponding to US Patent No. 4977138, which is incorporated herein by reference). FK 228 is preferably harvested from a strain belonging to the genus Chromobacterium, 25 which is capable of producing FK 228, because it can be obtained more easily. Synthetic or semi-synthetic FK 228 is also advantageous in that further purification step is not necessary or the number of steps can be reduced. Similarly, compounds A other than FK 228 can be also obtained by semi-3o synthesis or total synthesis by conventionally known methods.
To be more specific, it can be produced according to the method reported by Khan W. Li, et al. (J. Am. Chem. Soc., Vol. 118, 7237-7238(1996)).
The form of a pharmaceutically acceptable salt of compound A, or other HDAC inhibitors, includes salts with a base or an acid addition salt such as salts with inorganic base (e. g., alkali metal salts such as sodium salt, potassium salt etc., alkaline earth metal salts such as calcium salt, magnesium salt etc., ammonium salt), salts with an organic base (e. g., organic amine salts such as triethylamine salt, diisopropylethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt etc.), inorganic acid 1o addition salts (e. g., hydrochloride, hydrobromide, sulfate, phosphate etc.), organic carboxylic acid or sulfonic acid addition salts (e. g., formate, acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate etc.), salts with a basic or acidic amino acid s5 (e.g., arginine, aspartic acid, glutamic acid etc.) and the like.
The "topoisomerase II inhibitor'° in the present invention is a compound that binds to an active site of topoisomerase II
competitively with substrates, or a compound that binds to a 2o different site from active site of topoisomerase II to change the enzyme activity of topoisomerase II, and/or a compound that decreases the enzyme activity of topoisomerase II or otherwise inhibits enzyme activity. To be specific, anthracycline anticancer drugs, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide and the like, and pharmaceutically acceptable salts thereof and combinations thereof can be mentioned.
The anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, which is used as a topoisomerase II
3o inhibitor in the present invention, is not particularly limited.
Generally, amrubicin or a pharmaceutically acceptable salt thereof is not included in the scope of the present invention, which embodiment is described and claimed in copending application No. 334344/2003 filed in Japan on the same date as the patent application No. 334340/2003 filed in Japan forming the basis of this application. This copending application is incorporated herein by reference in its entirety. For example, aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin (adriamycin), pirarubicin and the like, and pharmaceutically acceptable salts thereof can be mentioned, with preference given to doxorubicin, daunorubicin and pharmaceutically acceptable salts thereof. The anthracycline anticancer drug or a pharmaceutically acceptable salt thereof may be used alone or so in a mixture of two or more kinds thereof.
In the present specification, the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is intended to exclude amrubicin and a pharmaceutically acceptable salt thereof, unless otherwise indicated.
15 As pharmaceutically acceptable salts of anthracycline anticancer drug, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide and the like, salts with a base or an acid addition salt such as salts with inorganic base (e. g., alkali metal salts such as sodium salt, potassium salt etc., alkaline earth 2o metal salts such as calcium salt, magnesium salt etc., ammonium salt), salts with an organic base (e. g., organic amine salts such as triethylamine salt, diisopropylethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-25 diben~ylethylenediamine salt etc.), inorganic acid addition salts (e. g., hydrochloride, hydrobromide, sulfate, phosphate etc.), organic carboxylic acid or sulfonic acid addition salts (e. g., formats, acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate 3o etc.), salts with a basic or acidic amino acid (e. g., arginine, aspartic acid, glutamic acid etc.) and the like can be mentioned.
In the present invention, the histone deacetylase inhibitor such as Compound A and the like, markedly enhances the antitumor activity of topoisomerase II inhibitor such as an anthracycline anticancer drug, a pharmaceutically acceptable salt thereof and the like. Thus, the antitumor agent and the antitumor effect enhancer of the present invention are useful as therapeutic drugs for cancer diseases including blood cancer and solid cancer, which are more specifically lung cancer, malignant lymphoma (e. g., reticulosarcoma, lymphosarcoma, Hodgkin's disease and the like), cancer of digestive organ (e. g., gastric cancer, gallbladder~bile duct cancer, pancreatic Zo cancer., liver cancer, colon cancer, rectal cancer and the like), breast cancer, ovarian cancer, chondrosarcoma (e. g., osteosarcoma and the like), bladder cancer, leukemia (e. g., acute leukemia such as acute inversion of chronic myeloid leukemia and the like), kidney cancer, prostate cancer and the s5 like .
The antitumor agent of the present invention is a combination of a histone deacetylase inhibitor and a topoisomerase II inhibitor (i.e., combination drug), and may be any as long as a histone deacetylase inhibitor and a ~o topoisomerase II inhibitor can be combined when in use for the administration. Therefore, the antitumor agent of the present invention may be a single preparation obtained by simultaneously preparing a histone deacetylase inhibitor and a topoisomerase II inhibitor, or a combined preparation 25 comprising two or more preparations obtained by separately processing a histone deacetylase inhibitor and a topoisomerase II inhibitor, as long as a histone deacetylase inhibitor and a topoisomerase II inhibitor can be combined when in use for the administration.
3o The form of administration is not particularly limited, and, for example, (1) administration of a composition comprising a histone deacetylase inhibitor and a topoisomerase II inhibitor, i.e., a single preparation, (2) simultaneous administration of two kinds of preparations obtained by separately processing the histone deacetylase inhibitor and the topoisomerase II inhibitor by the same administration route, (3) time staggered administration of two kinds of preparations obtained by separately processing a histone deacetylase inhibitor and a topoisomerase II inhibitor by the same administration route (e.g., administration in the order of a histone deacetylase inhibitor and a topoisomerase II inhibitor, or administration in reverse order), (4),simultaneous administration of two kinds of preparations obtained by separately processing a.histone deacetylase inhibitor and a topoisomerase II inhibitor by different administration routes, and (5) time staggered administration of two kinds of preparations obtained by separately preparing a histone deacetylase inhibitor and a topoisomerase II inhibitor by 25 different administration routes (e.g., administration in the order of a histone deacetylase inhibitor and a topoisomerase II
inhibitor, or administration in reverse order) and the like can be mentioned.
In the case of the time staggered administration, 2o moreover, it is preferred that a histone deacetylase inhibitor and a topoisomerase II inhibitor be co-present in the body for a time period necessary for the histone deacetylase inhibitor to reinforce the antitumor effect of the topoisomerase II
inhibitor. As such, it is preferred that the second inhibitor 25 is administered before the first inhibitor is cleared from the patient.
The enhancer of the present invention comprises a histone deacetylase inhibitor, and may be any as long as a histone deacetylase inhibitor and a topoisomerase II inhibitor can be so combined when in use for the administration. Therefore, as long as a histone deacetylase inhibitor is contained, the enhancer of the present invention may contain a topoisomerase II inhibitor in a single preparation. When it does not contain a topoisomerase II inhibitor, a topoisomerase II inhibitor can be administered separately as a combination drug.
The form of administration is not particularly limited, and, for example, (1) administration of an enhancer of the present invention, comprising a histone deacetylase inhibitor and a topoisomerase II inhibitor in a single preparation, (2) simultaneous administration of the enhancer of the present invention and a topoisomerase II inhibitor by the same administration route, (3) time staggered administration of the enhancer of the present invention and a topoisomerase II
so inhibitor by the same administration route (e. g., administration in the order of a topoisomerase II inhibitor and the enhancer of the present invention, or administration in reverse order), (4) simultaneous administration of the enhancer of the present invention and a topoisomerase II inhibitor by Zs different administration routes, and (5) time staggered administration of the enhancer of the present invention and a topoisomerase II inhibitor by different administration routes (e.g., administration in the order of a topoisomerase II
inhibitor and the enhancer of the present invention, or 2o administration in reverse order) and the like can be mentioned.
In addition, in the case of time staggered administration, both ingredients need to be co-present in the body as in the case of the above-mentioned antitumor agent.
In the present invention, the ratio of combination of the histone deacetylase inhibitor and the topoisomerase II
inhibitor is generally in the range of 1 . 100 to 100 . 1, preferably in the range of 1 . 10 to 10 . 1, in a weight ratio, whether they are prepared into a single preparation or separate preparations.
3o To enhance the antitumor effect of the present invention, administration along with ATRA (all-trans-retinoic acid) and other antitumor agents is also possible (e. g., administration as a single preparation, or simultaneous or sequential administration as separate preparations). In addition, the invention includes administering additional active agents that can treat or prevent side effects of one or more of the antitumor agents being administered.
The antitumor agent of the present invention can be used in the form of a pharmaceutical preparation such as a solid, semisolid or liquid preparation (tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, liquid, emulsion, suspension, syrup, injection etc.) containing a histone deacetylase inhibitor and/or topoisomerase II inhibitor to as an active ingredient, which is suitable for transrectal, intranasal, pulmonary, vaginal, external (topical), oral or parenteral (including subcutaneous, implantation, intravenous and intramuscular) administration.
The antitumor effect enhancer of the present invention z5 Can be used in the form of a pharmaceutical preparation such as a solid, semisolid or liquid preparation (tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, liquid, emulsion, suspension, syrup, injection etc.) containing a histone deacetylase inhibitor as an active ingredient, which 2o is suitable for transrectal, intranasal, pulmonary, vaginal, external (topical), oral or parenteral (including subcutaneous, implantation, intravenous and intramuscular) administration.
The antitumor agent and antitumor effect enhancer of the present invention can be also produced by conventional methods 2s using various organic or inorganic carriers conventionally used for forming pharmaceutical preparations, such as excipients (e. g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate etc.), condensation agents (e. g., cellulose, methyl cellulose, 3o hydroxypropyl cellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, starch etc.), disintegrants (e. g., starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, hydroxypropyl starch, sodium starch glycolate, sodium hydrogen carbonate, calcium phosphate, calcium citrate etc.), lubricants (e. g., magnesium stearate, aerosil, talc, sodium lauryl sulfate etc.), corrigents (e. g., citric acid, menthol, glycine, orange powder etc.), preservatives (e. g., sodium benzoate, sodium hydrogen sulfite, methylparaben, propylparaben etc.), stabilizers (citric acid, sodium citrate, acetic acid etc.), suspensions (e. g., methyl cellulose, polyvinyl pyrrolidone, aluminum stearate etc.), dispersants (e. g., hydroxypropylmethyl cellulose etc.), diluents (e. g., water etc.), wax base materials (e. g., cacao 2o butter, polyethylene glycol, white petrolatum etc.) and the like.
The antitumor agent and the antitumor effect enhancer of the present invention can be administered, without any particular limitation, in the form of the above-mentioned s5 conventional pharmaceutical preparations, to mammals inclusive of human. Particularly, they are preferably administered intravenously, intramuscularly or orally.
The dose in the present invention can be set to a lower level, as compared to an exclusive administration of a histone deacetylase inhibitor or a topoisomerase II inhibitor.
For example, the dose is selected appropriately depending on various factors such as the body weight and/or age of patients, and/or the degree of the symptom and an administration route. For example, when Compound A was added 2s as a histone deacetylase inhibitor, and an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof was added as a topoisomerase II inhibitor, the dose of a combination of Compound A and an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof for intravenous 3o administration is generally in the range of 1 to 1000 mg/day/m~
human body surface area, preferably in the range of 5 to 100 mg/day/m~ human body surface area, and more preferably 10 to 60 mg/day/m~ human body surface area by continuous drip infusion administration. In this case, the dose of Compound A is 0.1 to 100 mg/day/m2 human body surface area, preferably 1 to 50 mg/day/m2 human body surface area, and more preferably 5 to 30 mg/day/m~ human body surface area, wherein the dose of the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof to be administered is an amount obtained by subtracting the dose of Compound A from the combined dose of the above-mentioned Compound A and the anthracycline anticancer drug or the pharmaceutically acceptable salt thereof.
The present invention also provides a commercial package so comprising a combination drug containing a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination, except amrubicin and a pharmaceutically acceptable salt thereof, and a written matter associated with the combination drug, the written matter stating that the combination drug can or should 25 be used for an antitumor agent; and a commercial package comprising a preparation containing a histone deacetylase inhibitor, and a written matter associated with the preparation, the written matter stating that the preparation can or should be used for enhancing the antitumor effect of a topoisomerase 2o II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
Examples To demonstrate the usefulness of the present invention, the results of a pharmacological test are shown in the following.
Experimental Method 1 For an animal, 6 to 12-week-old female CDF1 mice (body weight: 17.2 to 24.7 g) were used at 5 to 12 mice per group.
Furthermore, female DBA/2 mice were used for the subculture of 3o tumor cells. For tumor, L-1210 mouse leukemia cells (hereinafter to be referred to as L-1210) were used. L-1210 cells subcultured intraperitoneally in DBA/2 mice were harvested and washed twice with a Hanks' solution. Dead cells were stained with trypan blue, viable cells were counted, and then the cells were suspended in a Hanks' solution, whereby the cells were adjusted to a predetermined number of cells. For the experiment, L-1210 cells (1 ~ 105 cells) were implanted intraperitoneally into the CDF1 mice.
The test compound was administered intraperitoneally into the mice once a day for 4 days, starting from the day after implantation of the tumor cells (dose: diluted test compound is administered at 10 ml/kg). In combined use experiment of the test compound, FK228 and the test compound were administered To sequentially.
All the antitumor effects were evaluated using prolonged life of mice as an index.
For the survival period of the mice, the survival was observed over 30 days or 60 days after tumor implantation, a 1s Median Survival Time (hereinafter to be referred to as MST) was determined and the life prolonging rate was calculated from the following formula:
MST of test compound 2o administration group Life prolonging rate = X 100 [T/C (%)] MST of control group The combination effect was determined by calculating a 25 Combination Index (C. I.) from the following formula, wherein C.I. > 1 was evaluated to be synergistic effect; C.I. - 1 was evaluated to be addition effect; and C.I. < 1 was evaluated to be no combination effect.
3o T/C [o] of FK228 and the test compound combined use group - 100 C.I.=
CT/C [ o ] of FK228 alone + rT/C [ o ] of test compound group - 100 I' alone group - 100 Test Compound 1 Adriamycin was dissolved in distilled water, and diluted with physiological saline. Other test compounds were dissolved in physiological saline, and then diluted with physiological saline.
Test Results 1 The results are shown in Table 1.
Table 1 Combination effect by combined use 1 [6 mice per group (12 mice per group for control group)]
Test compound Dose (mg/mg) T/C (%) C.I.
0.14 + 0 100 -FK228 + adriamycin 0 + 1 133 -0.14 + 1 178 2.36 The combined use of FK228 and adriamycin revealed a C.I.
of 2.36, which was evaluated to suggest a synergistic effect.
In addition, 2 mice out of 6 mice survived for 30 days.
As is clear from the results, the combined use of 0.14 mg/kg of FK228 ineffective by exclusive use and 1 mg/kg of adriamycin synergistically enhanced the antitumor effect thereof. Thus, FK228 is extremely useful as an antitumor effect enhancer.
Formulation Example 1 FK228 20 mg 2° physiological saline 4 ml FK228 (20 mg) is dissolved in and diluted with 4 ml of physiological saline to obtain a preparation for injection.
Formulation Example 2 FK228 20 mg doxorubicin hydrochloride 10 mg physiological saline 4 ml FK228 (20 mg) and doxorubicin hydrochloride (10 mg) are dissolved in and diluted with 4 ml of physiological saline to obtain a preparation for injection.
Tndustrial Applicability A histone deacetylase inhibitor (particularly Compound A) remarkably enhances the antitumor effect of a topoisomerase II
inhibitor.
Therefore, the antitumor agent of the present invention comprising a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination provides higher cancer treatment effects with a lower dose as compared to an exclusive administration of a~histone deacetylase inhibitor or a topoisomerase II inhibitor, and moreover, can decrease the side 25 effects to a lower level.
This application is based on patent application Nos.
334340/2003 and 344315/2003 filed in Japan, the contents of which are hereby incorporated by reference.
2o While this invention has been shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompasses by the appended claims.
All patents, patent publications and other publications identified or referenced herein are incorporated by reference in their entirety.
SEQUENCE LISTING
<110> Fujisawa Pharmaceutical Co., Ltd.
<120> Antitumor agent <130> 09678 <150> JP 2003-33434 0 <151> 2003-09-25 <150> JP 2003-34431 5 <151> 2003-10-2 <160> 1 <210> 1 <211> 4 <212> PRT
<213> Chromobacterium sp.
<220>
<221> MISC FEATURE
<222> (3) <223> Xaa is an amino acid represented by the formula NHa C ( CHCH3 ) COOH .
<220>
<221> SITE
<222> (1) , (2) , (4) <223> In the formula COOHCHZ CH (CHCHCZ H4 SH) OH, the carboxylic group is bonded with the amino group of the first amino acid Val, the hydroxyl group is bonded with the carboxylic group of the fourth amino acid Val, and the SH group is bonded with the SH group of the second amino acid Cys via a disulfide bond.
<400> 1 Val Cys Xaa Val
Claims (42)
1. An antitumor agent comprising a combination of a histone deacetylase inhibitor and a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
2. The antitumor agent of claim 1, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
3. The antitumor agent of claim 2, wherein the histone deacetylase inhibitor is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
4. The antitumor agent of claim 3, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
5. The antitumor agent of any of claims 1 to 4, which is used for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
6. An antitumor effect enhancer of a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof, which comprises a histone deacetylase inhibitor as an active ingredient.
7. The enhancer of claim 6, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
8. The enhancer of claim 7, wherein the histone deacetylase inhibitor is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
9. The enhancer of claim 8, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
10. The enhancer of any of claims 6 to 9, which is used for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
11. A method for treating a cancer, which comprises administrating, to a mammal, a combination of a histone deacetylase inhibitor and a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
12. The method of claim 11, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
13. The method of claim 12, wherein the histone deacetylase inhibitor is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
14. The method of claim 13, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
15. The method of any of claims 11 to 14, wherein the cancer is lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
16. A method of enhancing an antitumor effect of a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof, which comprises administrating an effective amount of a histone deacetylase inhibitor to a mammal.
17. The method of claim 16, wherein the topoisomerase II
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
18. The method of claim 17, wherein the histone deacetylase inhibitor is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
19. The method of claim 18, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
20. The method of any of claims 16 to 19, which enhances an antitumor effect against lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or
21. Use of a histone deacetylase inhibitor and a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof, for producing an antitumor agent.
22. The use of claim 21, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
23. The use of claim 22, wherein the histone deacetylase inhibitor is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
24. The use of claim 23, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
25. The use of any of claims 21 to 24, wherein the antitumor agent is used for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
26. Use of a histone deacetylase inhibitor for producing an antitumor effect enhancer of a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
27. The use of claim 26, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
28. The use of claim 27, wherein the histone deacetylase inhibitor is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, and the topoisomerase II inhibitor is an anthracycline anticancer drug
29 or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
29. The use of claim 28, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
29. The use of claim 28, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
30. The use of any of claims 26 to 29, wherein the antitumor effect enhancer is used for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, chondrosarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.
31. A pharmaceutical composition comprising, as active ingredients, a histone deacetylase inhibitor and a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
32. The pharmaceutical composition of claim 31, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
33. The pharmaceutical composition of claim 32, wherein the histone deacetylase inhibitor is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
34. The pharmaceutical composition of claim 33, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
35. A commercial package comprising a combination drug containing a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination, except amrubicin and a pharmaceutically acceptable salt thereof, and a written matter associated with the combination drug, the written matter stating that the combination drug can or should be used for an antitumor agent.
36. The commercial package of claim 35, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
37. The commercial package described in claim 36, wherein the histone deacetylase inhibitor is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
38. The commercial package of claim 37, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
39. A commercial package comprising a preparation containing a histone deacetylase inhibitor, and a written matter associated with therewith, the written matter stating that the preparation can or should be used for enhancing the antitumor effect of a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof.
40. The commercial package of claim 39, wherein the topoisomerase II inhibitor is at least one of an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof, etoposide, mitoxantrone, sobuzoxane, amsacrine, teniposide, and pharmaceutically acceptable salts thereof.
41. The commercial package of claim 40, wherein the histone deacetylase inhibitor is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, and the topoisomerase II inhibitor is an anthracycline anticancer drug or a pharmaceutically acceptable salt thereof, except amrubicin and a pharmaceutically acceptable salt thereof.
42. The commercial package of claim 41, wherein the anthracycline anticancer drug or a pharmaceutically acceptable salt thereof is at least one of aclarubicin, idarubicin, epirubicin, daunorubicin, doxorubicin, pirarubicin, and pharmaceutically acceptable salts thereof.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-334340 | 2003-09-25 | ||
JP2003334340 | 2003-09-25 | ||
JP2003344315 | 2003-10-02 | ||
JP2003-344315 | 2003-10-02 | ||
PCT/JP2004/014451 WO2005030239A2 (en) | 2003-09-25 | 2004-09-24 | Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2540108A1 true CA2540108A1 (en) | 2005-04-07 |
Family
ID=34380371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002540108A Abandoned CA2540108A1 (en) | 2003-09-25 | 2004-09-24 | Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
Country Status (14)
Country | Link |
---|---|
US (1) | US7314862B2 (en) |
EP (2) | EP2263694B1 (en) |
JP (1) | JP4779971B2 (en) |
AT (1) | ATE471740T1 (en) |
CA (1) | CA2540108A1 (en) |
CY (1) | CY1114359T1 (en) |
DE (1) | DE602004027824D1 (en) |
DK (1) | DK2263694T3 (en) |
ES (2) | ES2425083T3 (en) |
MX (1) | MXPA06003222A (en) |
PL (2) | PL1670514T3 (en) |
PT (1) | PT2263694E (en) |
SI (1) | SI2263694T1 (en) |
WO (1) | WO2005030239A2 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2298414C2 (en) * | 2001-08-21 | 2007-05-10 | Астеллас Фарма Инк. | Medicinal use of histon deacetylase inhibitor and method for assay of its anti-tumor effect |
EP1492596A1 (en) * | 2002-04-05 | 2005-01-05 | Fujisawa Pharmaceutical Co., Ltd. | Depsipeptide for therapy of kidney cancer |
EP1595952A4 (en) * | 2003-02-19 | 2008-05-21 | Astellas Pharma Inc | Method of estimating antitumor effect of histone deacetylase inhibitor |
EP1608628A2 (en) * | 2003-03-17 | 2005-12-28 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
PT2263694E (en) | 2003-09-25 | 2013-08-27 | Astellas Pharma Inc | Antitumor agent comprising the histone deacetylase inhibitor fk228 and the topoisomerase ii inhibitor doxorubicin |
US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
EP1824831A2 (en) * | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
JP2008540574A (en) * | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | Histone deacetylase inhibitor |
ZA200800901B (en) * | 2005-07-14 | 2010-05-26 | Takeda San Diego Inc | Histone deacetylase inhibitors |
WO2007040522A1 (en) * | 2005-09-30 | 2007-04-12 | The Ohio State Research Foundation | Antitumor agents |
EP1965824A4 (en) * | 2005-11-18 | 2011-10-19 | Gloucester Pharmaceuticals Inc | Metabolite derivatives of the hdac inhibitor fk228 |
WO2007084390A2 (en) * | 2006-01-13 | 2007-07-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
CA2650520A1 (en) * | 2006-04-24 | 2008-01-31 | Gloucester Pharmaceuticals | Treatment of ras-expressing tumors |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
JP2010514777A (en) * | 2006-12-26 | 2010-05-06 | ファーマサイクリックス,インク. | Methods for monitoring biomarkers using histone deacetylase inhibitors in combination therapy |
CN107090482A (en) | 2006-12-29 | 2017-08-25 | 细胞基因公司 | Prepare Romidepsin |
BRPI0720734A2 (en) * | 2006-12-29 | 2014-01-07 | Gloucester Pharmaceuticals Inc | ROMIDEPSIN PREPARATION |
WO2009002941A1 (en) * | 2007-06-22 | 2008-12-31 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by histone deacetylase inhibitors |
US20110021517A1 (en) * | 2008-02-26 | 2011-01-27 | Nerviano Medical Sciences S.R.L. | Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents |
RU2016149485A (en) * | 2010-07-12 | 2018-10-31 | Селджин Корпорейшн | SOLID FORMS OF ROMIDEPSIN AND THEIR APPLICATION |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
CN103917231B (en) | 2011-09-13 | 2016-09-28 | 药品循环有限责任公司 | Combination formulations of histone deacetylase inhibitor and bendamustine and application thereof |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
WO2014069255A1 (en) * | 2012-11-01 | 2014-05-08 | 公益財団法人微生物化学研究会 | Anticancer agent, and combination use anticancer agent |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
CN116327887B (en) * | 2023-04-24 | 2023-11-03 | 南京捷因诊断技术有限公司 | Application of LSD1 inhibitor as antitumor drug |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US486379A (en) * | 1892-11-15 | Hame-tug | ||
US574455A (en) * | 1897-01-05 | Switch-lock | ||
US3997633A (en) * | 1975-06-24 | 1976-12-14 | Max Leva | Contact towers with leak-proof support of improved plate subassembly |
US4315851A (en) * | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
US4348388A (en) * | 1980-04-02 | 1982-09-07 | G.D. Searle & Co. | 11-Amino-11-deoxydaunorubicin and analogs |
GB8426672D0 (en) * | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
US4950755A (en) * | 1985-08-12 | 1990-08-21 | Ohio State University | Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane |
US5242901A (en) * | 1988-01-27 | 1993-09-07 | New York University | Reduction of anthracycline induced cardiotoxicity |
GB8817743D0 (en) | 1988-07-26 | 1988-09-01 | Fujisawa Pharmaceutical Co | Fr901228 substance & preparation thereof |
JPH05507480A (en) * | 1990-05-26 | 1993-10-28 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 1,4-dihydropyridine for use in overcoming drug resistance |
US5620961A (en) * | 1994-04-25 | 1997-04-15 | Markovic; Nenad S. | Fructose ester-β-cyclodextrin complexes and processes for making and using same |
US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
US6020373A (en) * | 1995-10-20 | 2000-02-01 | Eastern Virginia Medical School | Chelate derivatives as protectors against tissue injury |
US5780054A (en) * | 1996-01-17 | 1998-07-14 | University Of British Columbia | Methods for increasing the circulation half-life of protein-based therapeutics |
US6451784B1 (en) * | 1996-12-30 | 2002-09-17 | Battellepharma, Inc. | Formulation and method for treating neoplasms by inhalation |
BR9713661A (en) * | 1996-12-30 | 2000-10-24 | Battelle Memorial Institute | Formulation and method for the treatment of neoplasms by inhalation |
US7229841B2 (en) * | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
US6286513B1 (en) * | 1998-10-22 | 2001-09-11 | Jessie L. Au | Methods for treating superficial bladder carcinoma |
US6197809B1 (en) * | 1998-12-23 | 2001-03-06 | Ardenia Investments Ltd. | Compounds for the treatment of cancer |
US20030144570A1 (en) * | 1999-11-12 | 2003-07-31 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
KR20100035666A (en) * | 1999-11-23 | 2010-04-05 | 메틸진 인크. | Inhibitors of histone deacetylase |
US6593308B2 (en) * | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
DK1438966T3 (en) | 1999-12-08 | 2007-06-11 | Cyclacel Pharmaceuticals Inc | Use of depsipeptide and analogs thereof as immunosuppressive compounds for the treatment of an infectious disease, an autoimmune disease, allergic reactions or hyperproliferative skin disease |
US20020028237A1 (en) * | 2000-04-20 | 2002-03-07 | Colbern Gail T. | Method for reducing toxicity of a cytotoxic agent |
ATE425177T1 (en) | 2000-07-17 | 2009-03-15 | Astellas Pharma Inc | REDUCED FK228 AND ITS USE |
WO2002024179A2 (en) * | 2000-09-22 | 2002-03-28 | Bristol-Myers Squibb Company | Method for reducing toxicity of combined chemotherapies |
AU2001290636A1 (en) * | 2000-09-22 | 2002-04-02 | Bristol-Myers Squibb Company | Method for reducing toxicity of combined chemotherapies |
US20020156023A1 (en) * | 2000-12-06 | 2002-10-24 | Tularik Inc. | Lometrexol combination therapy |
WO2002059375A2 (en) * | 2001-01-26 | 2002-08-01 | University Of Chicago | Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage |
ATE450265T1 (en) * | 2001-03-23 | 2009-12-15 | Shire Canada Inc | PHARMACEUTICAL MIXTURE FOR THE TREATMENT OF CANCER CONTAINING DIOXOLANE NUCLEOSIDE ANALOGUES |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
RU2298414C2 (en) * | 2001-08-21 | 2007-05-10 | Астеллас Фарма Инк. | Medicinal use of histon deacetylase inhibitor and method for assay of its anti-tumor effect |
EP1492596A1 (en) | 2002-04-05 | 2005-01-05 | Fujisawa Pharmaceutical Co., Ltd. | Depsipeptide for therapy of kidney cancer |
IL165214A0 (en) * | 2002-05-17 | 2005-12-18 | Aventis Pharma Sa | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
US20040136905A1 (en) * | 2002-10-15 | 2004-07-15 | Kent Thomas B. | Magnetically guided particles for radiative therapies |
US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
US20050222013A1 (en) | 2003-01-16 | 2005-10-06 | Georgetown University | Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy |
WO2004103358A2 (en) | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
PE20050206A1 (en) | 2003-05-26 | 2005-03-26 | Schering Ag | PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE |
CA2529840A1 (en) | 2003-06-27 | 2005-01-06 | Astellas Pharma Inc. | Therapeutic agent for soft tissue sarcoma |
PT2263694E (en) | 2003-09-25 | 2013-08-27 | Astellas Pharma Inc | Antitumor agent comprising the histone deacetylase inhibitor fk228 and the topoisomerase ii inhibitor doxorubicin |
US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
-
2004
- 2004-09-24 PT PT101635274T patent/PT2263694E/en unknown
- 2004-09-24 PL PL04773539T patent/PL1670514T3/en unknown
- 2004-09-24 AT AT04773539T patent/ATE471740T1/en active
- 2004-09-24 CA CA002540108A patent/CA2540108A1/en not_active Abandoned
- 2004-09-24 DE DE602004027824T patent/DE602004027824D1/en active Active
- 2004-09-24 ES ES10163527T patent/ES2425083T3/en active Active
- 2004-09-24 SI SI200432064T patent/SI2263694T1/en unknown
- 2004-09-24 DK DK10163527.4T patent/DK2263694T3/en active
- 2004-09-24 ES ES04773539T patent/ES2344899T3/en active Active
- 2004-09-24 JP JP2006515402A patent/JP4779971B2/en active Active
- 2004-09-24 MX MXPA06003222A patent/MXPA06003222A/en active IP Right Grant
- 2004-09-24 EP EP10163527.4A patent/EP2263694B1/en active Active
- 2004-09-24 WO PCT/JP2004/014451 patent/WO2005030239A2/en active Application Filing
- 2004-09-24 US US10/948,288 patent/US7314862B2/en active Active
- 2004-09-24 EP EP04773539A patent/EP1670514B1/en active Active
- 2004-09-24 PL PL10163527T patent/PL2263694T3/en unknown
-
2013
- 2013-09-09 CY CY20131100771T patent/CY1114359T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20050070467A1 (en) | 2005-03-31 |
CY1114359T1 (en) | 2016-08-31 |
WO2005030239A3 (en) | 2005-07-28 |
MXPA06003222A (en) | 2006-05-22 |
EP2263694B1 (en) | 2013-06-12 |
ES2344899T3 (en) | 2010-09-09 |
DE602004027824D1 (en) | 2010-08-05 |
ES2425083T3 (en) | 2013-10-11 |
WO2005030239A2 (en) | 2005-04-07 |
EP1670514B1 (en) | 2010-06-23 |
EP1670514A2 (en) | 2006-06-21 |
PL2263694T3 (en) | 2013-11-29 |
EP2263694A1 (en) | 2010-12-22 |
JP2007506647A (en) | 2007-03-22 |
US7314862B2 (en) | 2008-01-01 |
PT2263694E (en) | 2013-08-27 |
ATE471740T1 (en) | 2010-07-15 |
JP4779971B2 (en) | 2011-09-28 |
DK2263694T3 (en) | 2013-08-26 |
SI2263694T1 (en) | 2013-09-30 |
PL1670514T3 (en) | 2010-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1670514B1 (en) | Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor | |
US7951780B2 (en) | Antitumor agent | |
US7056883B2 (en) | Therapeutic agent for soft tissue sarcoma | |
US20050187148A1 (en) | Antitumor agent | |
US8673888B2 (en) | Depsipeptide for therapy of kidney cancer | |
JP3987909B2 (en) | Novel depsipeptide compounds | |
KR102387565B1 (en) | Pharmaceutical composition for preventing or treating cancer comprising streptonigrin and anticancer agent | |
JP2005120083A (en) | Antitumor agent | |
KR20050016331A (en) | Depsipeptide for therapy of kidney cancer | |
AU2013209841A1 (en) | Compositions and methods for treating cancer and inflammation-related diseases and conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20140121 |